The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors

Araujo-Fernandez, I; Delgado, J; Moscetti, L; Sarac, SB; Zander, H; Mueller-Egert, S; Dunder, K; Pean, E; Bergmann, L; Enzmann, H; Pignatti, F

Delgado, J (corresponding author), European Med Agcy, Oncol & Haematol Off, Domenico Scarlattilaan 6, F-108 HS Amsterdam, France.

ESMO OPEN, 2021; 6 (1):

Abstract

Immune checkpoint inhibitors have revolutionised cancer therapeutics. Translational research evaluating the role of biomarkers is essential to identif......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索